PC Logo Reverse BI

The Canadian Psychedelic Businesses Association

Newsroom

 

Members in The News

News Item — Jul 17, 2023

Empower Psychedelics preparing for clinical trials through the Special Access Program

Read

News Item — Jul 14, 2023

Check out MAPS Canada's ongoing seminars on fascinating issues related to psychedelic medicine and therapy through their #SchoolofPsychedelics.

Read

News Item — Apr 11, 2023

Filament Health And PharmAla Biotech Announce Release Of GMP MDMA Capsules

Read

News Item — Jul 26, 2022

Psyched Wellness Announces Findings From an Ongoing Study With the National Research Council of Canada

Read

News Item — Mar 28, 2023

Psyched Wellness Is Pleased to Announce Recent Neurobehavioral Study Evaluating Efficacy and Safety of AME-1

Read

News Item — Jul 28, 2022

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project

Read

News Item — Dec 04, 2022

A Canadian psychedelic drug company has created medical grade ayahuasca

Read

News Item — Feb 14, 2023

Filament Health Announces Second Psilocybin Supply Agreement With The Centre For Addiction And Mental Health

Read

News Item — Mar 15, 2023

Filament Health Announces FDA Approval Of Phase II Clinical Trial Studying Psilocybin For Methamphetamine Use Disorder

Read

News Item — Mar 24, 2023

Inside the Vancouver lab where scientists (legally) grow magic mushrooms

Read

News Item — Oct 11, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Read

News Item — Oct 06, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Read

News Item — Oct 26, 2022

SABI Mind Launches Equitable Access Program

Read

News Item — Feb 01, 2023

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Read

News Item — Mar 02, 2023

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Read

News Item — Sept 01, 2022

SABI Mind Introduces Specialized Ketamine Therapy for Chronic Pain

Read

News Item — Feb 01, 2023

First Alberta Clinical Site for Study of Psychedelic-Assisted Treatment for Alcohol Use Disorder Approved

Read

News Item — Oct 05, 2022

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

Read

News Item — May 20, 2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

Read

News Item — May 16, 2022

Ketamine Clinic in Kelowna

Read

News Item — May 12, 2022

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Read

News Item — May 12, 2022

SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies

Read

News Item — May 12, 2022

Psygen Receives Dealer's Licence from Health Canada

Read

News Item — May 12, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Read
 

Press Releases

Press Release — Jun 30, 2023

Canadian Psychedelic Medicine and Therapy Sector Welcomes Initial Federal Investment in Psychedelic Medical Research

Read

Press Release — Oct 06, 2022

Alberta government must engage with psychedelic sector for regulatory success

Read

Press Release — Sept 21, 2022

Canadian Psychedelics Industry Tells Policy Makers: Make Room for Healthcare Innovation

Read

Press Release — Aug 19, 2022

Globe and Mail: 'Fundamental value' in psychedelics remains despite market downturn

Read

Press Release — Jun 03, 2022

PSYCHEDELICS CANADA APPLAUDS HEALTH CANADA AND BC GOVERNMENT DECISION TO DECRIMINALIZE POSESSION OF SMALL AMOUNTS OF DRUGS

Read

Press Release — May 27, 2022

PSYCHEDELICS CANADA ANNOUNCES THE LAUNCH OF THE FIRST NATIONAL TRADE ASSOCIATION FOR LEGAL PSYCHEDELICS COMPANIES

Read

Media Inquiries
 

Contact Us